Serum immunoinflammation-related protein complexes discriminate between inflammatory bowel disease and colorectal cancer
- 65 Downloads
Inflammatory bowel disease (IBD) is an important risk factor for colon cancer. Novel serum immunoinflammation-related protein complexes (IIRPCs) have shown associations with early cancer detection. Herein, we investigated the potential of serum IIRPCs for discriminating between IBD and colorectal cancer (CRC) patients.
Serum protein complexes of 65 healthy controls, 57 CRC, 69 (ulcerative colitis) UC, and 67 (Crohn's disease) CD patients were isolated by native-PAGE. The gray values of serum IIRPCs bands in the gel were quantified using Quantity One software. The receiver-operating characteristic (ROC) curves were constructed to assess the discriminating ability by calculating the area under the ROC curve.
The serum IIRPCs levels in IBD and CRC patients were significantly elevated compared to healthy controls. ROC analysis indicated certain diagnostic ability of serum IIRPCs in differentiating IBD from CRC. Specifically, “a3” complex discriminated UC from CRC, with an AUC value of 0.722, sensitivity of 69.4% and specificity of 63.8%. Similarly, “b4” complex discriminated UC from CRC, with an AUC value of 0.709, sensitivity of 70.4%, and specificity of 60.0%. In addition, the “a3” complex also discriminated CD from CRC, with an AUC value of 0.785, sensitivity of 73.1%, and specificity of 74.1%, while the “b4” complex showed a tendency to discriminate CD from CRC, with an AUC value of 0.663, sensitivity of 67.9% and specificity of 50.0%. Thus, an equation based on multiple IIRPCs was built to further improve the discriminating power.
Serum IIRPCs can be used to discriminate IBD from CRC and may also be associated with early screening of colitis-associated cancer.
KeywordsImmunoinflammation-related protein complexes Inflammatory bowel disease Colorectal cancer Diagnosis
The authors thank to the staff in IBD clinic in Peking Union Medical College Hospital for assistance with research sample coordination; and all patients and healthy individuals who participated in this study.
This work was supported by a Health Research & Special Projects Grant of China (no. 201002020).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval and consent to participate
This study was approved by the ethic committee of Peking Union Medical College Hospital (PUMCH, approval number S-K462) and all serum were remains from clinical laboratory.
Written informed consent was obtained from all participants.
- 5.Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. Malignancies in patients with inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohn’s Colit. 2017;11:571–7.Google Scholar
- 12.Vucelić B, Milicić D, Krznarić Z, Korać B, Sentić M, Hadzić N, et al. Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease. Acta Med Aust. 1991;18:100–5.Google Scholar